With over 30 years of experience in the biopharmaceutical industry, Howard L. Levine, Ph.D., President and CEO of BioProcess Technology Consultants, Inc. (BPTC), is a proven executive with extensive strategic and operational experience in biopharmaceutical product development and commercialization.
Before founding BPTC and building it into one of the leading CMC consulting companies worldwide, Dr. Levine was Vice President of Manufacturing Operations at Repligen Corporation where he was responsible for all process development and manufacturing activities and Director, Pilot Plant Operations at Xoma Corporation, where he was responsible for the development and manufacture of monoclonal antibody products for clinical trial. He has also held positions in process development and manufacturing at Genentech and Amgen.
Dr. Levine is passionate about bringing new products to the market and has assisted in the development of over twenty different biological products and the successful commercialization of several of these products. In addition to leading BioProcess Technology Consultants, Dr. Levine is also Managing Director of BPTC Europe, a wholly-owned subsidiary of BioProcess Technology Consultants, established in September 2010 to provide local consulting services to the European Community.
He is a member of the Board of Directors of Protein Sciences Corporation and DNX Biopharmaceuticals, Inc., and member of the Scientific Advisory Board of Pall Life Sciences. Dr. Levine is also a member of the Editorial Advisory Board of BioPharm International Magazine, a frequently invited lecturer on manufacturing strategy, downstream processing, and commercialization of biotechnology products, and an author of numerous, peer-reviewed publications.
He holds a Ph.D. in chemistry from the University of Chicago and completed a post-doctoral fellowship at Harvard University.